BRISBANE, Calif. (AP) _ Aimmune Therapeutics Inc. (AIMT) on Thursday reported a loss of $62.9 million in its second quarter.
On a per-share basis, the Brisbane, California-based company said it had a loss of $1.01.
The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 93 cents per share.
Aimmune Therapeutics shares have dropped 19% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $19.34, a decline of 35% in the last 12 months.